STAREE-HEART: A randomized placebo-controlled trial of atorvastatin effects on a marker of cardiac aging in older individuals without prior cardiovascular disease events: Protocol and baseline description of participants - 27/08/25
, Thomas H. Marwick, PhD c, d, Rory Wolfe, PhD a, e, John Amerena, MBBS f, Andrea J. Curtis, PhD a, e, Ben Freedman, PhD g, Daniel J. Green, PhD h, David Kaye, PhD d, i, Amily Kolomoisky, BSc a, John J. McNeil, PhD a, Mark R. Nelson, PhD a, c, Christopher M. Reid, PhD a, j, Simone Spark, PhD a, e, Andrew M. Tonkin, MD a, Bing H. Wang, PhD d, i, Zhen Zhou, PhD a, Sophia Zoungas, PhD a, eHighlights |
• | Cardiovascular aging is associated with myocardial dysfunction, with consequent atrial fibrillation and heart failure. |
• | STAREE-HEART is a clinical trial assessing the effect of atorvastatin compared with placebo on markers of cardiovascular aging in a healthy older population. |
• | A total of 369 participants underwent a comprehensive cardiac evaluation before randomization, which will be repeated at 3 years. |
• | Atorvastatin may provide a population-wide prevention strategy for cardiovascular aging. |
ABSTRACT |
Background |
Statins may prevent myocardial dysfunction associated with aging, and consequent atrial fibrillation (AF) and heart failure (HF). STAREE-HEART is a randomized, double-blind, placebo-controlled clinical trial assessing atorvastatin on markers of cardiovascular aging in a healthy older population. This ancillary study is nested in the STAtins in Reducing Events in the Elderly (STAREE) primary prevention trial.
Methods |
Participants ≥ 70 years ( n = 369) have been randomized to atorvastatin or placebo. Assessment at baseline and 3-years includes echocardiogram, electrocardiography and blood collection for biomarker assessment. The primary endpoint is change in global longitudinal strain (GLS), a measure of left ventricular systolic function. An estimated 184 participants per group enables detection of mean GLS at 3 years in the placebo group being 2.0 percentage points lower than mean GLS in the statin group at 3 years, assuming SD = 5 percentage points and a 15% attrition rate, with power > 90%. We present summary statistics describing participants at baseline.
Results |
The mean age of the 369 STAREE-HEART participants was 73.0 years (SD 3.4). Mean left ventricular (LV) ejection fraction was 64.0% (SD 6.1), and mean GLS was 19.2% (SD 2.2). Mean GLS was similar between females and males (19.4% vs 19.0%) and slightly higher in those aged 70 to 74 compared to ≥75 years (19.4% vs 18.6%). AF was detected on screening in 4.5% of participants.
Conclusion |
The STAREE-HEART ancillary study will provide mechanistic detail concerning myocardial dysfunction and its consequences, to determine if atorvastatin affects left ventricular systolic function associated with aging.
Clinical trial registration |
clinicaltrials.gov. Unique identifier: NCT04536870.
Le texte complet de cet article est disponible en PDF.Plan
Vol 290
P. 140-152 - décembre 2025 Retour au numéro
Article précédent
- Electronically delivered, cardiovascular-focused messaging to improve influenza vaccination: Rationale, design, and baseline characteristics of the Kaiser Permanente VACCination Improvement with Nudge-based CardiovAscular Targeted Engagement (KP-VACCINATE) Megatrial
- Ankeet S. Bhatt, Alan S. Go, Rishi V. Parikh, Zoe Ballance, Thida C. Tan, Ben J. Marafino, Haihong Hu, Mark Mummert, Andrew P. Ambrosy, Gerardo Hernandez-Diaz, Rebecca Fitch, Svasti Patel, Tor Biering-Sørensen, Brian L. Claggett, Niklas Dyrby Johansen, Alexis Jones, Ivy A. Ku, Scott D. Solomon, Muthiah Vaduganathan, Benjamin Z. Galper, Kristine L. Lee, Natalia C. Berry, KP-VACCINATE Investigators
- Rationale and design of a registry-based randomized controlled study of personalized biomarker-based risk score-guided stroke prevention treatment in atrial fibrillation
- Ziad Hijazi, Lars Wallentin, Håkan Arheden, Anna Björkenheim, Viveka Frykman, Magnus Janzon, Annica Ravn-Fischer, Henrik Renlund, Anders Själander, Torbjörn Åkerfeldt, Jonas Oldgren
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?